^
Association details:
| Biomarker: | FLT3 overexpression |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Xospata (gilteritinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis
Published date:
08/19/2020
Excerpt:
In contrast, the more specific FLT3 inhibitor gilteritinib inhibited cell proliferation only in MM cells with higher FLT3 gene transcription (KMS12-PE and KMS12-BM), not in NCI-H929 displaying low amounts of FLT3 transcripts.
DOI:
https://doi.org/10.3390/cancers12092341
